Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITY-RBP4 in Healthy Volunteers and Stargardt Disease Type 1
NCT07836452Phase 1Recruiting
- Sponsor
- City Therapeutics
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CITY-RBP4 in Stargardt disease type 1 (STGD1) (4 arms), sponsored by City Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2026; status: recruiting.
02
Drugs
CITY-RBP4
03
Conditions
Stargardt disease type 1 (STGD1)
Beyond the preview
Go deeper on NCT07836452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836452.